GLP-1 Receptor Agonists May Improve Outcomes in Idiopathic Intracranial Hypertension

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 21, 2025.

via HealthDay

MONDAY, July 21, 2025 -- For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is associated with improved clinical outcomes compared with conventional therapies, according to a study published online July 14 in JAMA Neurology.

Georgios S. Sioutas, M.D., from the Virginia Commonwealth University Health System in Richmond, and colleagues conducted a retrospective cohort study using data from the TriNetX U.S. Collaborative Network between 2005 and 2024. Electronic health records from 67 health care organizations were referenced to examine initiation of GLP1-RA therapy within six months of IIH diagnosis. The control group included patients managed with conventional treatments, such as acetazolamide, topiramate, and dietary counseling.

A total of 44,373 patients with IIH were identified; the cohort included 555 GLP-1 RA users and 555 nonusers, after propensity score matching. The researchers found that use of GLP-1 RAs was associated with lower medication use, reduced headaches, visual disturbances or blindness, and papilledema (risk ratios, 0.53, 0.45, 0.60, and 0.19, respectively). The GLP-1 RA group also had a lower risk of procedures and mortality (risk ratios, 0.44 and 0.36, respectively), but no difference was seen between the groups in mean body mass index (BMI) at follow-up. Similar associations were seen in sensitivity analysis stratified by BMI (≥40 versus <40 kg/m2). Greater weight loss was seen in association with bariatric surgery, but better outcomes were seen in association with GLP-1 RA therapy.

"This retrospective multicenter study suggests GLP-1 RAs may benefit IIH management," the authors write. "However, prospective studies are warranted to validate these findings."

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-07-22 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords